65,437 trials
Schizophrenia
Primary: Brief Psychiatric Rating Scale (BPRS) Positive Symptom Domain Scores Between Minocycline and Placebo. — 14.5; 14.5; 12.9; 14.2 units on a scale
Malaria
Primary: Number of Subjects With Plasmodium Falciparum Parasitemia Following Sporozoite Challenge — 14; 10; 12 Participants — p=0.7675
Visual Disorder
Primary: Acceptable Lens Fitting — 1; 0.99 Proportion of eyes
Rheumatoid Arthritis
Primary: Percentage of Participants by Anti-Drug Antibody (ADA) Status Using Anti-PF-05280586 Antibody Assay — 3.5; 0.0; 15.2; 7.8 Percentage of Participants
Brain Injuries · Craniocerebral Trauma · Trauma, Nervous System
Primary: Ventilator-free Days — 16.2; 18.05 days
Breast Neoplasms
Primary: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples — 56.1; 44.4 Percentage of Participants — p=0.0126
Chronic Low Back Pain · Degenerative Disc Disease · Depression
Primary: Percent Change in Average Daily Pain Score — 38.6; 30.0; 20.6 percent change — p=0.01
Metastatic Castration-Resistant Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) — 8.1 Months
Lumbar Spinal Stenosis · Thoracic Spinal Stenosis
Primary: Change in Hemoglobin Level From Preoperative Appointment to Postoperative Hospital Discharge — -3.2; -4.6 grams per deciliter (g/dL) — p=0.1318
Atherosclerosis
Primary: Progression of Subclinical Atherosclerosis — 0.0044; 0.0078; 0.0100; 0.0088 mm per year
Atrial Fibrillation
Primary: Stroke (Primary Analysis) — 21.9; 29.3 Events per 1000 patient-years — p=0.0111
Bipolar Disorder
Primary: Hamilton Depression Rating Scale (HDRS) -17 Item; Baseline to End of Week 4 — 23.7; 13.3 units on a scale — p=<0.001
Pain
Primary: Pain Perception — 5.40303; 5.1457; 5.13171 units on a scale
Schizophrenia · Schizoaffective Disorder
Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90
Infections, Meningococcal
Primary: Number of Subjects With Vaccine Response to Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitidis Serogroup A, C, W-135 and Y (hSBA-MenA…